Hemorrhagic ocular complications associated with the use of systemic thrombolytic agents

Ophthalmology

Volumn 105, Issue 3, 1998, Pages 428-431

  Chorich, Louis J ^a,c   Derick, Robert J ^a   Chambers, Robert B ^a   Cahill, Kenneth V ^a   Quartetti, Eric J ^b   Fry, John A ^a   Bush, Charles A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Fox Valley Ophthalmology   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; GLAUCOMA; HEART INFARCTION; HUMAN; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE; NERVE COMPRESSION; OPTIC NERVE; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PROGNOSIS; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 0031918257     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(98)93023-8     Document Type: Article

References (18)

1. Grekos ZG, Schooken DD. Bilateral vitreous hemorrhages as a consequence of thrombolytic therapy successfully treated with vitrectomy in a patient without diabetes. Am Heart J 1995; 130(3 Pt 1):611-2.
2. Marcus DM, Frederick AR Jr. Streptokinase-induced Tenon's hemorrhage after retinal detachment surgery. Am J Ophthalmol 1994;118:815-7.
3. Khawly JA, Ferrone PJ, Holck DEE. Choroidal hemorrhage associated with systemic tissue plasminogen activator. Am J Ophthalmol 1996;121:577-8.
4. The Gusto Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
5. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
6. Schmidt D, Schumaker M, Wakhloo AK. Microcatheter urokinase infusion in central retinal artery occlusion. Am J Ophthalmol 1992;113:429-34.
7. Schumacher M, Schmidt D, Wakhloo AK. Intra-arterial fibrinolytic therapy in central retinal artery occlusion. Neuroradiology 1993;35:600-5.
8. Kessler CM, Druy E, Goldhaber SZ. Acute pulmonary embolism treated with thrombolytic agents: current status of tPA and future implications for emergency medicine. Ann Emerg Med 1988;17:1216-20.
9. Bero CJ, Cardella JF, Reddy K, et al. Recombinant tissue plasminogen activator for the treatment of lower extremity peripheral vascular occlusive disease. J Vasc Interv Radiol 1995;6:571-7.
10. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol 1994;118:559-68.
11. Kamei M, Tano Y, Maeno T, et al. Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Am J Ophthalmol 1996;121: 267-75.
12. Lundy DC, Sidoti P, Winarko T, et al. Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications. Ophthalmology 1996; 103:274-82.
13. MacCumber MW, McCuen BW II, Toth CIA, et al. Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil. Ophthalmology 1996;103:269-73.
14. Jaffe GJ, Abrams GW, Williams GA, et al. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmology 1990;97:184-9.
15. Verstraete M, Collen D. Pharmacology of thrombolytic drugs. J Am Coll Cardiol 1986;8(6 Suppl 8):33B-40B.
16. Califf RM, Fortin DF, Tenaglia AN, Sane DC. Clinical risks of thrombolytic therapy. Am J Cardiol 1992;69:12A-20A.
17. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993;328:673-9.
18. Zahn R, Koch A, Rustige J, et al. Primary angioplasty versus thrombolysis in the treatment of acute myocardial infarction. ALKK Study Group. Am J Cardiol 1997; 79:264-9.